SKI Market

A+| A| A-|

Indian Indices

Sensex

74,243.34 -116.67
( -0.16%)

Global Indices

Nasdaq

51,098.17 -484.76
(-0.94%)

Dow Jones

7,440.28 -165.03
(-2.17%)

Hang Seng

66,711.59 -759.10
(-1.13%)

Nikkei 225

10,374.30 13.98
(0.13%)

Forex

USD-INR

95.73 0.01
(0.01%)

EUR-INR

111.21 0.07
(0.06%)

GBP-INR

128.58 -0.06
(-0.05%)

JPY-INR

0.60 0.00
(0.01%)

YOU ARE HERE :
HOME
Markets
Equity
Company News Details

EQUITY - MARKET SCREENER

Ipca Laboratories Ltd

Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln

BSE Code

ISIN Demat

Book Value()

524494

INE571A01038

314.5139046

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

IPCALAB

36.1

41684.87

EPS(TTM)

Face Value()

Div & Yield %

45.52

Back

Accelya Solutions India consolidated net profit declines 29.32% in the March 2026 quarter

Apr 29,2026

Net profit of Accelya Solutions India declined 29.32% to Rs 21.38 crore in the quarter ended March 2026 as against Rs 30.25 crore during the previous quarter ended March 2025. Sales declined 0.47% to Rs 136.05 crore in the quarter ended March 2026 as against Rs 136.69 crore during the previous quarter ended March 2025.

Particulars	Quarter Ended
	Mar. 2026	Mar. 2025	% Var.
Sales	136.05	136.69	0
OPM %	25.28	33.92	-
PBDT	44.10	48.20	-9
PBT	29.53	41.73	-29
NP	21.38	30.25	-29

74,243.34 -116.67 ( -0.16%)

51,098.17 -484.76 (-0.94%)

7,440.28 -165.03 (-2.17%)

66,711.59 -759.10 (-1.13%)

10,374.30 13.98 (0.13%)

95.73 0.01 (0.01%)

111.21 0.07 (0.06%)

128.58 -0.06 (-0.05%)

0.60 0.00 (0.01%)